Pharmaceutical companies are aggressively looking into development of drugs for patients suffering from type-2 diabetes mellitus. We read about Priamal, Indian pharma company, entering into phase-II trial with its P1736-05 compound. Sanofi reported results of phase–III trial, GetGoal clinical trial program. The program was designed to assess the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes.
About the study
Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. The study included:
- Population of 361 patients with type 2 diabetes.
- randomly receipt of either lixisenatide, the Sanofi’s diabetes injectable, or a placebo treatment.
- Observation of patients for three months
- lixisenatide monotherapy administered once daily significantly improved glycemic control with a pronounced postprandial effect.
- therapy had an acceptable safety profile in patients with type 2 diabetes.
Lixisenatide’s mode of action...
includes controling blood sugar by increasing insulin production, thereby slowing the body’s absorption of sugar. It is part of the new GLP-1 class of diabetes drugs. Other pharma giants are also working on this class of drugs, such as Byetta, marketed by Eli Lilly & Co. and Amylin Pharmaceuticals Inc, and Novo Nordisk’s Victoza. There are some safety concerns this regarding GLP-1 class drug like Novo Nordisk’s Victoza was approved with a warning about the risk for thyroid cancer and the requirement of a risk-mitigation strategy.
Source: Associate Press